跳至主要内容
临床试验/ACTRN12611000969965
ACTRN12611000969965终止2 期

A randomized controlled trial of intra-arterial reperfusion therapy after standard dose intravenous t-PA within 4.5 hours of ischemic stroke onset utilizing dual target vessel occlusion and penumbral mismatch imaging selection

Florey Institute of Neuroscience and Mental Health0 个研究点目标入组 100 人开始时间: 2011年9月9日最近更新:
适应症

试验速览

阶段
2 期
状态
终止
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • 1. Patients presenting with anterior circulation acute ischaemic stroke eligible using standard criteria to receive IV tPA within 4.5 hours of stroke onset
  • 2. Patient, family member or legally responsible person depending on local ethics requirements has given informed consent
  • 3. Patient's age is >/=18 years
  • 4. Intra-arterial clot retrieval treatment can commence (groin puncture) within 6 hours of stroke onset.
  • Imaging inclusion criteria
  • Dual target:
  • 5. Arterial occlusion on CTA or MRA of the ICA, M1 or M2
  • 6. Mismatch - Using CT or MRI with a Tmax >6 second delay perfusion volume and either CT-rCBF or DWI infarct core volume.
  • a) Mismatch ratio of greater than 1.2, and
  • b) Absolute mismatch volume of greater than 10 ml, and
  • c) Infarct core lesion volume of less than 70m

排除标准

  • 1. Intracranial haemorrhage (ICH) identified by CT or MRI
  • 2. Rapidly improving symptoms at the discretion of the investigator
  • 3. Pre-stroke mRS score of >/= 2 (indicating previous disability)
  • 4. Inability to access the cerebral vasculature in the opinion of the neurointerventional team
  • 5. Contra indication to imaging with MR with contrast agents
  • 6. Participation in any investigational study in the previous 30 days
  • 7. Any terminal illness such that patient would not be expected to survive more than 1 year
  • 8. Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study.
  • 9. Pregnant women (clinically evident)
  • 10. Previous stroke within last three months
  • 11. Recent past history or clinical presentation of ICH, subarachnoid haemorrhage (SAH), arterio-venous (AV) malformation, aneurysm, or cerebral neoplasm. At the discretion of each Investigator.
  • 12. Current use of oral anticoagulants and a prolonged prothrombin time (INR > 1.6)
  • 13. Use of heparin, except for low dose subcutaneous heparin, in the previous 48 hours and a prolonged activated partial thromboplastin time exceeding the upper limit of the local laboratory normal range.
  • 14. Use of glycoprotein IIb - IIIa inhibitors within the past 72 hours. Use of single or dual agent oral platelet inhibitors (clopidogrel and/or or low-dose aspirin) prior to study entry is permitted.
  • 15. Clinically significant hypoglycaemia.
  • 16. Uncontrolled hypertension defined by a blood pressure > 185 mmHg systolic or >110 mmHg diastolic on at least 2 separate occasions at least 10 minutes apart, or requiring aggressive treatment to reduce the blood pressure to within these limits. The definition of aggressive treatment” is left to the discretion of the responsible Investigator.
  • 17. Hereditary or acquired haemorrhagic diathesis
  • 18. Gastrointestinal or urinary bleeding within the preceding 21 days
  • 19. Major surgery within the preceding 14 days which poses risk in the opinion of the investigator.
  • 20. Exposure to a thrombolytic agent within the previous 72 hours

研究者

发起方
Florey Institute of Neuroscience and Mental Health

相似试验